Unlike MDM2 inhibitors, USP7 inhibitors were well tolerated in mice at doses that effectively inhibited tumor growth (Chauhan et al., 2012; Fan et al., 2013; Tavana et al., 2016), suggesting that pharmacological inhibition of USP7 may be safer than inhibition of MDM2. Here, USP7 is linked to neoplasm.